Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by KPOIndustrieson May 05, 2020 10:08pm
144 Views
Post# 30990951

RE:In Excess of 250,000 test prices at $49usd-125usd

RE:In Excess of 250,000 test prices at $49usd-125usd

why is it at 0.14 then?? Shouldn't it be at 0.60?? So why no institutional investors? Why no big money? Why no buy-out? It doesn't add up. We've been saying "just wait, be patient" since we were at 0.60 back in the GeneNews days. Where are we now? Fu$k, this thing was 0.03 a few weeks ago. 

 

Northerencents wrote: For those on the board that can't read between the lines 

This is the initial orders valued between 12.5 million us -31.25 million us 

keyword initial 
keywords 1 out of 3 test 
key words in excess 
key point this can be achieved in a maximum timeframe of 2.5 months Max! 

the companies financials are breaking out +++12x-31X  millllionsssss although I need one billllllllllllion dollars 


how long do you think it will take for this to become hard fact and the Sp to follow 

 

Bullboard Posts